Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
Dateline City:
KENILWORTH, N.J. & AMES, Iowa
rVSV-ZEBOV-GP (V920) Now Being Studied in Three Key Safety and Efficacy Clinical Trials
KENILWORTH, N.J. & AMES, Iowa--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the
third, late-stage, clinical trial of their Ebola vaccine candidate
rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine
candidate was originally developed by the Public Health Agency of
Canada’s National Microbiology Laboratory and licensed to NewLink
Genetics in 2010. On Nov.
Language:
English
Contact:
Merck Media:Pam Eisele, 267-305-3558orImraan Munshi, 215-652-0059Investor:NewLink Genetics:Jack Henneman, 515-598-2561orMerck:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: NLNK Exchange: NASDAQ
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Ebola Newsroom Corporate News Latest News Source Type: news
More News: Clinical Trials | Ebola | Ebola Vaccine | Genetics | Health | International Medicine & Public Health | Laboratory Medicine | Merck | Microbiology | Pharmaceuticals | Vaccines